BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 25, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 19, 2020

View Archived Issues
2-19-Acutus-Acqmap.png

FDA gives nod for next-gen Acutus cardiac mapping algorithm to enable more precise ablation

Acutus Medical Inc. is working to build itself into a major competitor in cardiac electrophysiology. The latest step to do so is an FDA clearance for its second-generation cardiac mapping software known as Supermap. This works in conjunction with its next-gen Acqmap 3D Imaging and Mapping System. The Carlsbad, Calif.-based startup, which was founded in 2011, is now marketing these in both the U.S. and Europe, where Supermap received a CE mark in October 2019. Read More
Psychiatric-Disorders.png

Enclear scoops up $10M in series A funds for novel neurodegenerative disease treatment

Cambridge, Mass., startup Enclear Therapies Inc. has secured $10 million in series A financing led by 20/20 Healthcare Partners. The company is developing a device to aid in treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid (CSF). Read More
Cancer-cells-pic.png

Nantomics’ deep learning algorithm provides fast identification of cancer marker

Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer. The company said their approach is a rapid and cost-effective way to establish the breast cancer subtype, thus giving clinician and patient alike a good understanding of which therapies would be ineffective for that cancer and maximizing the chances for a cure. Read More
2-19-bionano-saphyr.png

Bionano Genomics sees encouraging results from study of Saphyr

The results from a study comparing San Diego-based Bionano Genomics Inc.’s Saphyr to traditional cytogenetic methods for the clinical analysis of leukemia genomes revealed that the system was 100% concordant with the standard of care for the detection of somatic chromosomal abnormalities. Read More
pill over molecule structures

Nicoya launches world’s first digital benchtop SPR system to accelerate drug discovery

TORONTO – Kitchener, Ontario-based Nicoya Life Sciences Inc. has followed up CA$10 million (US$7.6 million) in series A funding raised in January with its launch of “the world’s first digital benchtop surface plasmon resonance (SPR) system” to boost development of drug therapies. Read More
Genes-cells-DNA

AAAS 2020: Progress in Human Cell Atlas unveiling underlying mechanisms of disease

SEATTLE – As it enters its third year, the Human Cell Atlas project has mapped 100 million of 100 billion cells, and by comparing gene expression profiles of normal and aberrant cells and building networks of cellular interactions, is leading to breakthroughs in understanding of disease at a molecular level. Read More

Financings for Feb. 19, 2020

Med-tech firms raising money in public or private financings, including: Catalent, Innerscope Hearing Technologies, Myomo, Pixium Vision, Veravas. Read More

In the clinic for Feb. 19, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: BBS-Bioactive Bone Substitutes, Nantomics, Nanthealth. Read More

Other news to note for Feb. 19, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott Laboratories, Amalgam Rx, Biocorp, Breezie, Carbon22, Caresyntax, Cicero Diagnostics, Co-Diagnostics, Conduent, Dexcom, Diabeloop, Diversified, Dreamed Diabetes Ltd., Exalenz Bioscience, Insulet, Isage Rx, Konica Minolta Healthcare Americas, Medable, Meridian Bioscience, Novastep, Qiagen, Regenlab USA, Scipher Medicine, Spok, Vitaltech, Vis.ai, Wilsonpro, Zap Surgical Systems. Read More

Regulatory actions for Feb. 19, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Canon Medical Systems USA, Conavi Medical, Endoclot Plus, Flowonix Medical. Read More

Regulatory front for Feb. 19, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Advamed, Resmed, Abbott Vascular, Teleflex Medical. Read More

BioWorld MedTech’s Orthopedics Extra for Feb. 19, 2020

Keeping you up to date on recent developments in orthopedics, including: In2bones reports U.S. Launch of the Avenger radial head prosthesis; Searching for biomarkers and therapeutic agents against breast cancer; MRI findings predict shoulder stiffness for rotator cuff tears. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing